ContextVision AB (0L8Z), the Sweden-based medical technology software company listed on the Oslo Stock Exchange under ticker CONTX, has published an update on its ongoing share buy-back programme, revealing that 115,034 additional shares were purchased across six trading days between 29 October and 6 November 2026. The programme, managed by DNB Carnegie on the company's behalf, has an overall budget of up to NOK 12,000,000 and covers a maximum of 2,000,000 shares. As of the latest disclosure, ContextVision holds a total of 4,178,662 of its own shares, representing 5.40% of the company's share capital. Investors tracking capital allocation at the medical imaging specialist may note the programme remains active until 29 January 2027.

Key Points

  • ContextVision AB (0L8Z), listed on the Oslo Stock Exchange as CONTX
  • DNB Carnegie executed 115,034 shares purchased across six sessions from 29 October to 6 November 2026 under the company's buy-back mandate
  • Accumulated programme total stands at 1,320,785 shares at a weighted average price of NOK 4.7667, with total spend of NOK 6,407,235.86
  • Investors should watch whether the remaining programme capacity of approximately 679,215 shares is utilised before the 29 January 2027 deadline

Weekly Buy-Back Transactions Show NOK 520,400 Deployed Between 29 October and 6 November 2026

DNB Carnegie carried out purchases on five of the six available trading days in the reporting window. The largest single-day volume was 28,764 shares on 29 October at a weighted average price of NOK 4.4274, generating a daily transaction value of NOK 128,163.75. The smallest parcel was 10,480 shares on 4 November at NOK 4.3999 per share, totalling NOK 46,986.03. No shares were purchased on 2 November 2026. Daily weighted average prices across the period ranged from NOK 4.2670 to NOK 4.6676, illustrating modest price variation during the reporting week.

ContextVision's Cumulative Buy-Back Reaches 1,320,785 Shares at NOK 6.4 Million Spent

Including previously disclosed purchases, ContextVision has now accumulated 1,320,785 shares under the programme at a weighted average price of NOK 4.7667, with total expenditure of NOK 6,407,235.86. The programme, which launched on 10 September 2026, authorises repurchases of up to 2,000,000 shares within a maximum budget of NOK 12,000,000. With roughly 679,215 shares and approximately NOK 5.59 million of budget remaining, the programme retains meaningful capacity ahead of its January 2027 close, according to the announcement.

ContextVision's AI-Driven Medical Imaging Software Underpins Capital Return Strategy

Founded in 1983 and headquartered in Sweden, ContextVision describes itself as a global market leader in image enhancement software for medical imaging equipment. The company supplies proprietary artificial intelligence and image analysis software to manufacturers of ultrasound, X-ray, and MRI systems worldwide, with local representation in the United States, Japan, China, and South Korea. Its software is designed to assist clinicians in interpreting medical images, supporting diagnostic accuracy. The buy-back programme was disclosed under obligations arising from the EU Market Abuse Regulation and Section 5-12 of the Norwegian Securities Trading Act, with CFO Richard Hallström named as the authorising publication contact.